Accelerating research progress for brain cancer

Patients with rare cancers often face limited options for treatment, particularly given the fact that it is challenging to design clinical trials that enroll enough patients with these rare cancers to thoroughly test new therapies. This is very much the case for many brain cancers, which tend to be rare, deadly, and resistant to typical cancer therapies. In an effort to help counter this trend, Baylor Scott & White Research Institute (BSWRI) is actively pursuing research aimed at bringing more trial opportunities, and ultimately, potential future treatment options to patients with cancers of the brain. A notable advantage that BSWRI brings to this effort is its ability to link multiple sites across the Baylor Scott & White system under their clinical trials. In doing so, BSWRI is able to engage a more diverse population, and therefore more potentially eligible patients, across not only in the state of Texas, but neighboring states.

Read more

Lipoprotein (a): new patient-centered recommendations for evaluating the risk of heart disease

Lipoprotein (a), also known as Lp(a), has been long suspected to be an independent risk factor for cardiovascular disease (CVD). Some studies have estimated that 20% of the Caucasian U.S. population may have increased CVD risk due to elevated plasma Lp(a) levels. However, until recently, a lack of robust assays to measure Lp(a) levels has prevented scientific consensus on the nature of Lp(a)-associated risk.

Read more

Pacemaker implantation and dependency after TAVR

Findings from REPRISE III (The Repositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus Valve System—Randomized Clinical Evaluation), as published in the Journal of the American Heart Association, present new insights around incidence and proposed predictors of pacemaker implantation and pacemaker dependency after TAVR.

Read more

Pathology preparedness and a scalable pandemic response

The 2020 COVID-19 pandemic associated with the novel SARS-CoV-2 virus has required an unprecedented mobilization of resources worldwide. One of the cornerstones to pandemic response is rapid initiation of widespread testing. To meet this need, physicians and researchers at Baylor Scott & White Research Institute were quick to establish reliable testing for SARS-CoV-2 virus, and their experience can serve as a guide for the response to future novel infectious diseases.

Read more

Baylor University Medical Center performs 1,000th heart transplant

Baylor University Medical Center, part of Baylor Scott & White Health, in fall 2020 performed its 1,000th heart transplant. Consistently ranked as a national leader in cardiovascular healthcare, Baylor Dallas is the largest heart transplant program in Texas, having performed more heart transplants than any other program in the state, including many multi-organ transplants, such as heart-kidney and heart-liver. Baylor Dallas also has the shortest wait time from listing to transplant in the state.

Read more